Roivant Q1 net income $57.5M, cash $5.7B; pipeline advances in MG, DM, NIU

Roivant Sciences Ltd.

2024-Q1 EPS reported $0.12 revenue$55,132,000

Net income of $57.5M vs net loss of $327.8M YoY; diluted EPS $0.12 vs ($0.38).
Total revenue $55.1M, product revenue $18.4M from VTAMA; license/milestone $36.8M.
Cash, cash equivalents and restricted cash $5.7B at June 30, 2024, reflecting $648M share repurchase.
Immunovant completed enrollment in batoclimab pivotal MG trial; brepocitinib Phase 3 VALOR in DM completed enrollment.
Priovant to initiate Phase 3 for brepocitinib in NIU; VTAMA PDUFA action expected Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.